热景生物(688068.SH)：拟对舜景医药增资3.71亿元

Group 1 - The company, Hotgen Biotech (688068.SH), plans to increase its investment in Beijing ShunJing Biopharmaceutical Technology Co., Ltd. by 371 million yuan at a price of 26.5 yuan per registered capital, acquiring 400,000 shares from Lishui Qiaoda Venture Capital Partnership [1] - Following the capital increase and share acquisition, the company's ownership in ShunJing Biopharmaceutical will rise from 43.1842% to 50.2340%, making it a controlling subsidiary and consolidating it into the company's financial statements [1] - To enhance long-term incentives and motivate the core team of ShunJing Biopharmaceutical, the company will implement a stock incentive plan through a newly established platform, ShunZhiYe Enterprise Management Partnership [1] Group 2 - The stock incentive plan is conditional, requiring either the addition of at least two new INDs approved by the National Medical Products Administration or the successful progression of the clinical trial for the innovative drug SGC001 by March 31, 2027 [2] - The incentive will primarily target core employees and certain directors and executives of the company, with specific execution details to be determined by ShunJing Biopharmaceutical's management [2] - If the conditions for the stock incentive are not met, 50% of the granted shares will be repurchased and canceled by ShunJing Biopharmaceutical at the original investment amount plus the bank deposit interest rate [2]